Glioblastoma, IDH-wildtype Clinical Trials in New York, New York
5 recruitingNew York, New York
Showing 1–5 of 5 trials
Recruiting
Phase 1Phase 2
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Recurrent Glioblastoma, IDH-WildtypeRecurrent MGMT-Methylated Glioblastoma
National Cancer Institute (NCI)97 enrolled36 locationsNCT05432804
Recruiting
Phase 1
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-MutantRecurrent Adult Diffuse Midline Glioma, H3 K27-Mutant+4 more
National Cancer Institute (NCI)30 enrolled42 locationsNCT06860594
Recruiting
Phase 1
A Study of 177Lu-PSMA-617 in People With Gliomas
GliomaGlioblastoma, IDH-wildtypeDiffuse Midline Glioma, H3 K27-Altered+1 more
Memorial Sloan Kettering Cancer Center20 enrolled7 locationsNCT07223034
Recruiting
Phase 1
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
GlioblastomaGBMGlioblastoma Multiforme+4 more
Orbus Therapeutics, Inc.66 enrolled8 locationsNCT05879367
Recruiting
Phase 3
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
Brain CancerGlioblastomaGBM+4 more
Northwell Health432 enrolled1 locationNCT05271240